This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.
Not a healthcare professional? Browse:
This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.
What's new
Congresses & Events
13 December, 2024
DEMETHER is a single-arm phase II trial to evaluate the efficacy and safety of subcutaneous pertuzumab and trastuzumab maintenance after induction treatment with trastuzumab deruxtecan for previously untreated HER2+ advanced breast cancer.
Congresses & Events
13 December, 2024
A micro-economic analysis was conducted to evaluate the total cost of care of mosunetuzumab compared with alternative novel treatment options in patients with third-line or later relapsed/refractory follicular lymphoma. Comparisons of the total cost of care of these therapies from a United States third-party payer perspective are presented.
Congresses & Events
13 December, 2024
A cost-effectiveness analysis was conducted, using a simulated partitioned survival model with health states of progression-free survival, post-progression survival, and death, to compare mosunetuzumab with alternative treatment options. The cost-effectiveness of these therapies from a United States payer perspective are presented.
Congresses & Events
13 December, 2024
Disparities in breast cancer (BC) outcomes between high-income and low-income countries result from social determinants and limited access to mammography screening, leading to later diagnoses and poorer prognoses. Understanding and addressing the barriers to BC care are critical for improving clinical outcomes and achieving the World Health Organization's 2021 Global Breast Cancer Initiative ambition (to reduce BC mortality by implementing early detection, timely diagnosis, and comprehensive BC management). This poster presents the findings from a systematic literature review of the barriers that women face in accessing mammography screening, diagnosis, and BC treatment. An estimation of the number of women worldwide affected by delays or lack of access to medical services is also reported.
Congresses & Events
12 December, 2024
Efficacy and safety of tiragolumab + atezolizumab + chemotherapy vs pembrolizumab + chemotherapy in patients with advanced non-squamous NSCLC from the Phase 2/3 SKYSCRAPER-06 study.
Congresses & Events
12 December, 2024
IMscin002: Exploratory analyses from the IMscin002 trial exploring patient strength of preference for atezolizumab subcutaneous vs intravenous for the treatment of NSCLC, according to baseline characteristics, number of injections, and injection duration.
Congresses & Events
12 December, 2024
This poster presents Phase Ic data evaluating the safety and efficacy of ZN-1041 in combination with trastuzumab and capecitabine, for the treatment of Chinese patients with HER2+ breast cancer brain metastases and extracranial disease.
Congresses & Events
12 December, 2024
Congresses & Events
12 December, 2024
Congresses & Events
12 December, 2024
pionERA Breast Cancer is a Phase 3 study of first-line giredestrant vs fulvestrant, both combined with a cyclin-dependent kinase 4/6 inhibitor, in participants with estrogen-receptor positive, HER2-negative locally advanced/metastatic breast cancer with resistance to prior adjuvant endocrine therapy. Methods for the study are reported.
Ask us a question and request information about Roche products or services.
If you have experienced potential side effects with a Roche product you can report it here.
If you suspect a potential defect or a Roche product has not met your expectations you can report it here.
Request an assessment if your product was stored outside the recommended temperature range.
On this global platform you will find tailored, evidence-based, balanced, and up-to-date medical information from Roche.This website is intended to provide medical information relating to questions asked about Roche medicines.
This website is not country specific and therefore may contain medical information on Roche medicines that is not applicable to your country. Please refer to your country prescribing information and local package insert.
Some medical information contained on this site may not be consistent with the locally approved indications for the specific Roche medicine. If you are a patient on a Roche medicine, please contact your treating doctor for medical support and before making any changes to your treatment.